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A B S T R A C T
Recently, research has shed new light on the role of Prohibitin (PHB) in cancer pathogenesis across an
array of cancer types. Important mechanisms for PHB have been unveiled in several cancers, especially
with regard to the androgen independent state of prostate cancer (PC) and oestrogen dependent breast
cancer. However, PHB is often overlooked due to its complex but subtle roles within the cell. Having gath-
ered both historical and current research exploring PHB’s role in different cancer types including prostate
and breast, here we aim to pair this information with its molecular properties in the hope of translating
this information into a clinical perspective, thus discussing its possible use in future cancer therapy.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Ubiquitously expressed prohibitin (PHB), also known as B-cell-
receptor-associated protein 32 (BAP 32), along with its homologue
PHB2 (BAP 37) are evolutionally conserved proteins expressed in
an array of eukaryotic organisms [1]. Indeed the PHB sequence is
highly conserved across species as evidenced by mouse and rat PHB
protein-coding sequences only differing from the human se-
quence by one amino acid [2].
The PHB gene, ﬁrst identiﬁed in the 1980s, is located on chro-
mosome 17q21 and consists of two alleles. One allele expresses an
exon 6 associated single strand conformation polymorphism (SSCP)
identiﬁed by cleavage at a polymorphic intronic EcoRI site. The
second allele however, is not cleaved in a similar manner [3]. PHB
mRNA transcribes for the PHB protein that has a molecular weight
of 32 kDa and comprises of 272 amino acid residues. PHB belongs
to a family of proteins which have an evolutionary conserved
prohibitin-like domain, otherwise known as band-7 family of pro-
teins, along with a transmembrane domain at the N-terminus and
a coiled-coil domain at the C terminus [3] (Fig. 1). The structure of
the PHB protein lacks motifs characteristic for signal transduction,
nuclear localisation, ATP binding sites or transcriptional factors [3].
McClung’s group initially observed PHB exhibiting an anti-
proliferative function and thus acknowledged it as a protein with
tumour suppressor characteristics [3]. The cellular functions of PHB
have since been recognised in aging, inﬂammation and obesity,
however, the molecular functions of PHB in carcinogenesis are still
to be fully clariﬁed [5].
Cellular location
Mitochondrial PHB
In mammalian cells PHB is considered a mitochondrial marker
as this is where staining is most prominent. The PHB protein complex
foundwithin themitochondria embodies two subunits, namely PHB1
and PHB2, which physically associate with one another and share
more than 50% identical amino acid homology [1,5,6]. The C-terminal
coiled co-domain is responsible for the interaction of the two sub-
units, PHB1 and PHB2, which together form heterodimers [7]. These
heterodimers organise into ring like structures which establishes
the integrity of the mitochondrial structure and regulates
mitochondrial function [3]. PHB1 and PHB2 aﬃx into the innermem-
brane of the mitochondria via hydrophobic stretches at the
N-terminal [5]. Upon deletion of the PHB2 gene, PHB1 is also reduced
suggesting that they are mutually dependent on one another. The
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Fig. 1. Image displaying schematic representation of the human PHB gene. NH2 = N
terminal, COOH = C terminal, adapted from [4].
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mitochondrial role of PHBwas ﬁrst seen in a C. elegansmodel, where
loss of PHB resulted in fragmentation and disorganisation of the mi-
tochondria in comparison to control mitochondria, which appeared
to be elongated and well structured. The discovery that it was loss
of PHB causing the disruption of the mitochondrial structure, was
conﬁrmed by the observation that loss of PHB2 resulted in deteri-
oration of optic atrophy 1 (OPA1) [4]. OPA1 has a speciﬁc function
in governing the formation of mitochondrial cristae and resides with
the inner mitochondrial membrane. The interaction between PHB
and OPA1 was exhibited by PHB depleted mouse embryonic ﬁbro-
blasts (MEF) cells showing a highly similar fragmentation pattern
which was also seen in OPA1 down-regulated MEF cells [4].
PHB can also partake within the dynamics of the mitochon-
dria. For example, stomatin-like protein (SLP-2) can form a subunit
with PHBwithin the inner mitochondrial membrane to form a trans-
membrane protein [8,9]. Upon depletion of SLP-2 in HeLa cells,
proteolysis of PHB1 and PHB2 ensued, suggesting PHB stability is
dependent upon SLP-2 during mitochondrial stress [8], which is of
particular relevance as SLP-2 holds importance in the biogenesis and
activity of the mitochondria [10].
In a yeast model, PHB1 transports into the mitochondria, com-
bines with Tim8/13 complexes allowing for the biogenesis of
transmembrane proteins within the intermembrane space of the
mitochondria [8]. There has also been evidence that PHB func-
tions as a chaperone for newly made proteins which form parts of
the mitochondrial complex 1 [11]. PHB can also act as a scaffold,
enlisting membrane proteins into a lipid environment, essential for
mitochondrial morphogenesis [4].
The localisation of PHBwithin themitochondrial membranemay
hold importance in preventing apoptosis in yeast and mammalian
cells, against metabolic stress [12]. Accumulating evidence sug-
gests that PHB1 also plays a role in preventing oxidative stress in
an array of cell lines. For example, oxidative stress occurring in the
intestinal epithelial cells results in a drop in PHB1 levels a trend also
observed in ex vivo lung tissue undergoing hypoxia [13]. Further-
more, knockdown of PHB1 in endothelial cells resulted in
mitochondria produced reactive oxidative species (ROS) due to a
blockade of the electron transport chain [14]. Conversely, over-
expression of PHB1 in cardiomyocytes served as a protective
mechanism against hydrogen peroxide induced injury and main-
tained the structure mitochondrial membrane [2].
Nuclear localisation of PHB
The roles and location of PHB have been extensively deﬁned in
themitochondria, however, recent evidence dependent on cell types,
also exhibits a role for PHB located within the nucleus [2].
A study showed that PHB was localised to the nucleus and cy-
toplasm of LNCaP prostate cancer cells [8]. Moreover, PHB was
consistently expressed in the nucleus of these cultured human pros-
tate cancer cells, interacting with E2F transcription factors –
suppressing their function and causing the recruitment of HDAC-1
and N-CoR [8]. Further, data from this study suggested that in trans-
formed cells PHB translocated from the nucleus towards the
mitochondria in response to apoptotic signalling [8]. Export of PHB
out of the nucleus is complex as it is usually bound to other pro-
teins such as retinoblastoma protein (Rb) and is therefore unable
to undergo passive diffusion through the nuclear membrane. Instead
PHB exports from the nucleus via short amino acid stretches known
as nuclear export signals [15]. This well-deﬁned nuclear export signal,
similar to the most common type of export sequence seen in the
HIV virus and type 1 rev protein, has a core of large hydrophobic
amino acids such as leucine which are recognised by the CRM-1
export receptor [15,16]. This receptor aids in the nuclear transport
of PHB, as the removal of nuclear export signals inhibits the trans-
port of PHB out of the nucleus. PHB was also shown to localise in
the nucleus of breast cancer cells but re-localises to the cyto-
plasm in camptothecin-treated cancer cells [17]. This also indicates
that PHB undergoes transport out of the nucleus upon receiving
apoptotic or stress signalling. This transportation of PHB out of the
nucleus in response to camptothecin appeared to eliminate its in-
teraction with the E2F1 transcription factor in the nucleus [17].
The PHB gene is differentially expressed in the testes and ovaries.
Within the rat ovary, PHB is localised to the granulosa cells and
oocyte cells. Interestingly, PHB studies in rat ovaries revealed that
PHB translocates from the cytoplasm into the nucleus in atretic fol-
licles, germinal vesicle-stage oocytes, zygotes and blastocytes [18]
suggesting PHB has a regulatory role in the nucleus of theca-
interstitial cells in the ovum throughout follicular maturation.
Observed PHB expression within these cell types was ample when
compared to proliferating-cell nuclear antigen (PCNA) expression
during follicular maturation, suggesting a positive correlation with
anti-proliferating cells and PHB expression [19]. Similarly, within
rat testes, expression of PHB was not noted in actively dividing
spermocytes [19]. This could be linked to PHB interactingwith steroid
receptors such as the androgen and oestrogen receptor.
The ability of PHB to translocate to various subcellular loca-
tions in response to different signals, along with regulating E2Fs and
P53 raises the idea that depending on the environment it is placed
in, it can either promote apoptosis or proliferation, a property that
is rather unique.
Membrane bound PHB
Enrichment of PHB has been observed within the lipid rafts of
the plasma membrane. Further evidence has also demonstrated the
shedding of PHB into the circulation by cancerous colon cells [20].
In addition, PHB has also been shown to be involved in the Raf sig-
nalling pathway altering epithelial cell adhesion and migration. The
direct interaction of PHB with C-Raf is needed for the localisation
and phosphorylation of C-Raf at serine 338 at the plasma mem-
brane [20]. The localisation of PHB to the plasma membrane has
also been shown to have an immunology link as evidence sug-
gests it associates with the IgM receptor [21].
PHB and cell cycle machinery components
There is a complex combination of factors and proteins which
regulate the progression of the mammalian cell cycle. Members of
the Rb family and their downstream targets such as members of
the E2F family are examples of proteins which are heavily in-
volved in the progression of the cell cycle [22]. Mis-regulation of
these proteins has been inﬂuenced in the onset of multiple cancer
types [23] and therefore it is interesting to note how PHB inter-
acts with members of the E2F family to suppress their activity. Rb
and its family members; p107 and p130 repress the G1/S phase tran-
sition, however cyclin D phosphorylates Rb, allowing the transition
to the S phase to take place [22]. Studies showed that PHB can bind
to all three family members of the Rb family with robust eﬃcien-
cy [24] even though PHB lacks the canonical LXCXEmotif whichmost
Rb binding proteins have. However, unlike other Rb binding pro-
teins such as cyclin D, PHB does not have a negative effect on Rb’s
function, instead it heightens its function much like Brg1 protein.
Wang et al. also found that PHB can bind to the E2F1-5 family
members unlike Rb which can only bind to E2F1-,3 [24] thus sug-
gesting that PHB binds to a domain which is common amongst all
the family members of the E2Fs. It was also shown that PHB could
suppress the transcriptional activity of E2F1 in T47D cells [24]. There
is also evidence to suggest that there are potential mechanisms in-
dependent of Rb which allows the suppression of E2Fs by PHB.
Interestingly, the suppression of E2Fs via PHB cannot be reversed
when the adenovirus E1A protein is added, however this is the case
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with regard to Rb’s suppression of E2Fs [24]. E1A can disrupt the
interaction of Rb and E2Fs in the activation domain, allowing E2F
to be uninhibited. It is likely that PHB prevents E1A from carrying
out this function and thus suppression of E2Fs is enabled even in
the presence of E1A. Overall, there is an established relationship
between PHB, Rb, E2Fs and cell proliferation [24] based upon the
evidence that PHB lacking a Rb binding domain cannot suppress E2Fs
nor cellular proliferation. A statement which can be considered ac-
curate as E2Fs heavily inﬂuences proliferation [24]. Speciﬁcally, E2F1
inhibition via PHB occurs through a putative coiled-coil domain, and
it is this region alone that could hinder the transcriptional activity
of E2F1.
Further studies on PHB could unveil mechanisms associating PHB
and the regulation of the cell cycle (Fig. 2) which is vital in uncov-
ering information regarding the initiation of cancer.
Multiple roles and associations of the PHB protein in diseases
and cancer
PHB is known to interact with proteins that regulate cell cycle
progression as well as hinder DNA replication in numerous cell types.
PHB also interacts with several transcription factors that have in-
tegral roles in diseases and carcinogenesis. The remainder of this
review will predominately focus on the role PHB has in prostate
cancer (PC) and breast cancer.
PHB, the androgen receptor and PC
PC is a heterogeneous disease initially driven by the androgen
receptor (AR). Circulating androgens cause the activation of the AR
leading to the transcription of androgen responsive genes [25]. Thera-
pies targeted against the AR e.g. anti-androgens are initially
successful. However, as the disease progresses it becomes refrac-
tory to hormonal interventions and is therefore classiﬁed as androgen
independent which currently remains an incurable stage of the
disease. Often however, PC is still driven by the AR even in the ap-
parent absence of androgens, leading to ‘apparent androgen
independent disease’. Hence, there is a deﬁnite need to establish
mechanisms underpinning androgen independent PC (AIPC), and
why treatment options often fail [26,27].
PHB overexpression represses AR induced gene activation, and
suppresses tumour growth of AR-dependent LNCaP xenografts. In
the absence of PHB, or in cells with lowered PHB expression levels,
prostate cancer cells have been shown to become sensitive to low
levels of androgens and indeed to weaker adrenal androgens [28].
PHB loss may therefore contribute to AIPC by reducing the threshold
in which PC cells may respond to low levels of androgens or weak
androgen-like hormones [28].
A study carried out a comprehensive gene expression analysis
of 152 human samples divided into normal tissue, PCa tissue, normal
adjacent tissue andmetastatic tissue. Analysis was carried out using
the Affymetrix U95a, U95b and U95c chip sets. Results are freely
published as a Geodatabase (GSE6919) [28,29]. Fig. 3 above ** rep-
resents analysis of the PHB gene across PC tissue samples. A one-
way ANOVA test was carried out and signiﬁcance was measured
against the normal tissue.
The interactions between AR and PHB are complex. Firstly, it was
noted that PHB protein levels were diminished by 50% in LNCaP
lysates following androgen stimulation for 16 hours [12]. A similar
trend (30% decrease) was seen in the metastatic and androgen in-
dependent cell line PC-3 which had been stably transfected with
the androgen receptor (AR) [12]. To further demonstrate the inter-
action of the AR signalling pathway and PHB, a study highlighted
that a decrease in PHB levels either via androgen stimulation or siRNA
mediated knock down, triggered enhanced growth of xenografts in
mice, due to increased AR activity [30]. An alternative study [31]
used proteomic analysis to identify signiﬁcant changes in protein
expression of 23 needle biopsies from patients considered high risk
for PC. This conﬁrmed that PHBwas highly elevated in PC, as opposed
to benign prostatic hyperplasia (BPH). The elevated PHB expres-
sion was also noted at an mRNA level [26].
The relationship between androgen stimulation and PHB was
further established when increasing concentrations of
Dihydrotestosterone (DHT), up to 100 nM, caused complete repres-
sion of PHB protein expression on a Western Blot [12]. Stimulation
of PHB overexpressing LNCaP cells with DHT failed to enter the cell
cycle with 97% of the cell population remaining in the G1 state, com-
pared to 80% of the non-transfected cells entering the cell cycle [12].
Furthermore, the importance of PHB down-regulation has also been
assessed. Small inhibitory RNA (si-RNA) oligos complementary to
either exon 1 of PHB or to the 3’UTR of PHB were designed and
stably transfected into LNCaP cells. FACs analysis of cell cycle entry
PHB
E2Fs
Rb
Brg1/Brm
HDAC
E2F binding site E2F responsive gene
Fig. 2. Schematic representation of where PHB binds to E2Fs and Rb, causing the
recruitment of HDACs. Image adapted from [12].
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Fig. 3. Geodatabase analysis. Expression analysis of PHB levels between normal tissue,
PCa tissue, primary tumour andmetastatic tissue. **p value <0.001, ***p value <0.0001.
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highlighted that cells containing PHB si-RNA had an increase in cell
population entering the S/G2 M phase. Speciﬁcally 2% of these cells
were seen in this phase when compared to control cells, which in-
creased to 10% after DHT stimulation [27].
Thus, there is a wealth of evidence to say that PHB has a major
role in the onset of PC, especially in terms of the initiation of an-
drogen independent tumours [32]. However, how the tumour
acquires a decrease in PHB levels via androgen stimulation still needs
to be further elucidated. Moreover, there may also be other mecha-
nisms that completely bypass the AR signalling pathway, causing
a down-regulation of PHB, that also needs to be fully understood.
Fig. 4 describes the current knownmechanism involving the AR and
PHB.
Interactions of PHB, anti-androgens and the AR
As the AR signalling pathway is central to the initiation and de-
velopment of PC, the main therapy available is the administration
of androgen antagonists [33]. Interestingly, PHB was shown to
enhance the eﬃciency of androgen antagonists. Androgen antago-
nists were shown to induce the recruitment of PHB and the ATP
dependent helicase BRG1 to androgen responsive promoters, in-
hibiting the translocation of the AR, and thus increasing the eﬃciency
of antagonist-mediated growth inhibition of prostate cancer cells
[34]. Moreover, the recruitment of BRG1 to the PSA promoter was
dependent on PHB, suggesting that prohibitin suppresses AR de-
pendent transcription via a mechanism involving BRG-1 mediated
chromatin remodelling in the presence of androgen antagonists [34].
PHB, the ER and breast cancer
More than 70% of primary breast cancers are initiated by the oes-
trogen receptor (ERα). The activation of the ERα by oestrogen
intensely increases the proliferation andmetastatic potential of breast
cancer cells [35]. With breast cancer remaining the most common
cancer in women worldwide [36], and with countries which pre-
viously had low breast cancer incidence showing increases, it is
essential to note the role PHB has in this cancer.
Tamoxifen inhibits the interaction between oestrogen and ERα
and there is evidence demonstrating that PHB improves the eﬃ-
cacy of standard treatment for ERα positive patients. This could be
through the PHB homologue PHB2, which can bind to ERα repress-
ing its transactivation to the nucleus, thus enhancing the effectiveness
of tamoxifen bound ERα [37]. Within the same study, PHB was also
identiﬁed as an ERα co-repressor in several other cell lines includ-
ing, themonkey kidney CV1 and cervical cancer HeLa cells suggesting
PHB’s role is not cell type speciﬁc [37]. A regulator of the oestrogen/
ERα signalling pathway known as BIG3 was thought to co-localise
with PHB2 in the cytoplasm rendering PHB2 unable to repress ERα
transcriptional ability, thus potentially contributing to tamoxifen
resistance in ERα positive breast cancer [35]. To overcome BIG3 re-
pressing PHB2, a dominant negative peptide named ERAP has been
identiﬁed to competitively bind to PHB2, preventing its interac-
tion with BIG3 thus allowing PHB2 to suppress ERα activity, leading
to complete suppression of ERα positive breast cancer cell prolif-
eration both in vivo and in vitro and thus perhaps offering a solution
to inhibiting the development of tamoxifen resistance [35].
Additionally, both PHB and PHB2 were shown to repress SRC-3
activation of ERα. This is extremely important as SRC-3 is a known
co-activator of ERα and is frequently ampliﬁed in breast cancer [38].
To further conﬁrm this, anti-sense PHB2 RNA causes a heightened
fold increase in ERα transactivation, highlighting that endogenous
PHB2 dulls the stimulatory effect oestrogen has on ERα. Although
themechanism to how PHB2 counteracts SRC-3’s function still needs
to be deﬁned, it is clear that PHB and PHB2 compete with SRC-3
for the ERα receptor, causing the recruitment of HDACs, suppress-
ing ERα activation [37]. To further highlight PHB’s role in oestrogen
signalling co-repression, knock out of PHB in a murine model re-
sulted in a hypoplastic uterus and impaired U2-induced uterus
proliferation [39]. Moreover, during early pregnancy, mRNA levels
of PHB found in the uterus of mice were heightened by 2-fold 2 days
post-coitum. As blastocyst implantation occurred 4.5 days post-
coitum, this high expression of PHB prior to the implantation
suggests its role in maintaining the implantation status of the blas-
tocyst [39]. Furthermore, in the same study, treatment of
ovariectomized mice with oestrogen resulted in an increase in PHB
mRNA transcripts in 6 hours [39]. This suggests that PHB is a prob-
able target of oestrogen in the uterus as well as mammary tissue.
Overall, there are clear results indicating that PHB is an oestrogen-
regulated gene both in vivo and in vitro.
PHB, Stat3 and irritable bowel syndrome
PHB has also been seen to exhibit its function in inﬂammatory
diseases which often lead to cancer development [40], especially
as it is associatedwith oxidative stress. A known transcriptional factor
Stat3 (Signal transducer and activator of transcription 3) is acti-
vated via various ligands in an array of tissues. Interestingly, data
[41] suggests that there is a link between mitochondrial Stat3 and
PHB in the intestinal epithelium. It is thought that this interaction
prevents mitochondrial dysfunction and it is this process that is dis-
rupted in the pathogenesis of Irritable bowel syndrome (IBS).
Phosphorylation of Stat3 occurs at serine 727 (S727) which is nec-
essary for the mitochondrial function of Stat3 and PHB interaction
[42]. Co-immunoprecipitation determined that PHB interacts with
pS727-Stat3 in the mitochondria of cultured intestinal epithelial cell
lines and in vivo in mouse colonic epithelium [41]. This PHB-pS727-
Stat3 interaction is lowered throughout mitochondrial stress in
response to TNF-α by the means of lowered PHB expression.
However, upon PHB overexpression, PHB-pS727-Stat3 interaction
is preserved during TNF-α induced stress [43]. It has been recognised
that PHB expression levels are lower in inﬂamed epithelia of IBS
patients when compared to healthy controls, signifying that down-
regulation of PHBmay be an event in the early onset of pathogenesis
rather than a downstream effect of the disease [41]. A transgenic
model over-expressing PHB in intestinal epithelial cells demon-
strated an up-regulation of protection against experimental colitis
and there was notably less oxidative stress present in the colon [41].
As previously mentioned, mitochondrial dysfunction is a familiar
feature seen in cancers [44] due to reactive oxidative species (ROS)
and loss of mitochondrial chaperones such as PHB. A recent report
believed that loss of PHB led to the onset of dysplasia during ul-
cerative colitis [41]. Moreover, PHB protein expression found
in colonic mucosa was decreased after mice were induced with
DHT
AR nucleus
No AR translocation to the nucleus. No 
induction of steroidal response genes.  No 
cell proliferation
PHB
Fig. 4. Schematic representation of PHB repressing the translocation of the AR-
DHT complex towards the nucleus, thus transcription of androgen responsive genes
is halted. Image adapted from [1].
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experimental colitis-associated cancer and vice versa [41]. Thus it
is theorised that PHB could potentially prevent the onset of tumours
by aiding mitochondrial stability. By targeting Stat3, one could
enhance PHB’s function to regulate mitochondria function that could
theoretically aid intestinal epithelial cells homeostasis during colitis
where PHB is lost. Mechanism is shown in Fig. 5.
The role PHB has within IBS only offers more evidence to help
evaluate approaches on the incorporation of PHB with cancer
therapies.
PHB in other cancer types
As PHB has been showed to have a huge implication in PC and
breast cancer, a functional role has also been noted in ovarian and
bladder cancer. Firstly, in line with PHB aiding apoptosis, it was noted
that up-regulation of PHB was seen in normal ovarian cells under-
going apoptosis in the presence of gonadotropin releasing hormone
(GnRH) [45]. As this was seen in the mitochondria, this emphasises
that PHB is maintaining the mitochondrial integrity and loss of PHB
may be associated with defective apoptosis in ovarian cancer. This
may be the reason why PHB accumulation was seen in the peri-
nuclear and cytoplasmic regions in the epithelial cells in papillary
serous ovarian tumour cells [45]. On the other hand, in bladder
cancer PHB up-regulation was shown to be associated with the pro-
liferation of bladder cancer cells through PHB1’s phosphorylation
at thr258 by AKT [46]. In the same study it was also observed that
up-regulation of PHB, at both a transcriptional and translational
levels, in bladder cancer tissue were associated with poorer bladder
cancer prognosis when compared to normal adjacent urothelial tissue
[46]. PHB phosphorylation has also been observed in response to
insulin signalling causing PHB to interact to a lesser extent with PIP3
[47]. This may disrupt PHB’s ability to attenuate the PI3K pathway,
which often is aberrant in cancers [47].
PHB and miRNAs
PHB-untranslated region (UTR) and miRNAs
Where the coding region is 95–100% similar in the PHB gene
across species, the UTR of the highly conserved PHB gene shows high
variability across mammals, as indicated in Table 1.
Alignment analyses of PHB’s UTR across mammals indicate there
is variation amongst mammals (Fig. 6). Table 1 demonstrates the
percentage similarities between species along with the genetic dif-
ferences between them. The variations in the UTR region of PHB
across species and themultiplemiRNA target sites suggest it is widely
and variably regulated, however this is not the case for the PHB
protein, although the UTR could regulate ‘ﬁne tuning’ of the PHB
protein.
It is interesting to note some of these miRNA targets on PHB’s
UTR are classiﬁed as oncogenic such as miR-27a [26] (Fig. 7). There-
fore, theoretically administration of the PHB-UTR absent of the PHB
protein could act as a miRNA ‘sponge’ [48].
PHB interacts with MicroRNAs in PC
One mechanism which could potentially bypass the AR signal-
ling pathway is PHB’s interaction with miR-27a.
MicroRNAs are small noncoding strands of RNA, usually around
25 nucleotides long, and can control gene expression by mRNA deg-
radation or inhibition of protein production [49]. Interestingly,
microRNA gene locations are often found in cancer associated genes
or in fragile sites, making them vulnerable to single nucleotide
PHB pS727-Stat3
Mitochondrial 
stress/ROS/metabolic dysfunction
Stress signalling pathways
Fig. 5. Schematic representation of the interaction between PHB and pS727-Stat3,
stopping stress signalling pathway activation. Image adapted from [2].
Table 1
Similarities of PHB-UTR sequence across mammalians.
Name Name Similarity (%)
Human Chimp 98.93
Human Mouse 71.44
Human Rat 68.66
Human Dog 75.05
Human Horse 80.36
Human Cow 78.52
Human Chicken 49.17
human 0.00302
chimp 0.0077
Mouse 0.0555
rat 0.05
chicken 0.35419
dog 0.12072
horse 0.08206
cow 0.1191
Fig. 6. Phylogram of PHB-UTR genetic differences betweenmammalian species. (NCBI,
aligned in ALGGEN).
Fig. 7. miRNA targets within PHB’s UTR in humans, mice and rats. Similar targets
across species are indicated in red. Dissimilar targets indicated in black. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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polymorphisms (SNPs), thus allowing for the acquisition of either
oncogenic or tumour suppressive characteristics [30]. It is there-
fore no surprise that microRNAs can become aberrantly activated
during carcinogenesis, taking on oncogenic characteristics – named
oncomiRs. In particular an oncomiR known as miR-27a located on
chromosome 19 position p13.1, is encoded by a intergenic cluster
along with both miR-23a and miR-24-2 [30]. The expression of this
particular cluster has been modiﬁed in numerous cancers such as
leukaemia and ovarian cancer [50]. Remarkably, its function can have
opposing effects, for example in hepatocellular carcinoma, up-
regulation of this cluster can hinder TGFβ’s ability to suppress tumour
growth [51]. On the other hand, in human embryonic kidney cells,
it can up-regulate apoptosis [52]. It is probable that post-
transcriptional modiﬁcation plays a role in these clusters alternative
functions within different cellular environments [30]. With regard
tomiR-27a, it was proven by Fletcher et al. that upon androgen stim-
ulation PHB expression was down-regulated, allowing target gene
expression and thus PC cell growth. It was predicted that a binding
site for miR-27a was found within the highly conserved 3’ UTR of
the PHB gene. This was conﬁrmed by a luciferase reporter assay,
which veriﬁed down-regulation of this UTR in response to andro-
gen treatment, suggesting this region’s susceptibility to androgen
regulated miRNAs, hindering its activity. This mechanism was due
to degradation of the PHB gene transcript rather than post-
transcriptional modiﬁcation/inhibition. To demonstrate that miR-
27a possesses characteristics of an oncogene, manipulation of miR-
27a caused an upsurge in androgen responsive genes such as PSA
and TMPRSS2 [30]. Several other targets of miR-27a have been iden-
tiﬁed such as the tumour suppressor gene FOXO1, ZBTB10, a repressor
of the Sp family of transcriptional factors and Wee-1 a vital regu-
lator of cyclin B. Moreover, it is likely that miR-27a only weakens
PHB protein expression rather than causing complete reduction, and
it is likely that miR-27a targets other proteins associated with cell
proliferation resulting in growth stimulation [30]. It is known that
miRNAs based therapies for cancer intervention provides an excit-
ing way to counteract tumorigenesis for integrated cancer treatment
[53], therefore miR-27a could be an ideal candidate.
Avenues for cancer therapy
The lack of mutations within the PHB gene suggests its func-
tion is essential, as no clearly functional mutations were found in
its chromosomal location in 32 men diagnosed with PC [54]. There-
fore the lack of PHB mutations may hold the key for PHB targeted
therapies such as microRNA based inhibitory oligos or drugs such
as ﬂavagline drugs.
Direct administration of PHB into cells can increase cellular stress
and therefore other therapeutic avenues must be considered. miRNA
therapy could provide a solution potentially using MiR-27a as a
target. Especially as manipulation of certain miRNAs in cancers have
minimal side effects [55]. More than 20 miRNA targets are under-
going clinical trials, emphasising the vast amount of research
surrounding this category of treatment. However, the downfall with
miRNA-targeted therapy comes with problems surrounding the de-
livery, stability and the potential of activating an immune response
[55].
Interestingly novel potent anticancer agents have been discov-
ered to also affect the activity of PHB. One such example is a natural
product known as ﬂavaglines that have been studied as PHB ligands
[3]. Flavaglines display selective anticancer activities and have also
been shown to enhance chemotherapies in several mouse models
and display no signs of toxicity [56]. As PHB is known to interact
with p53 in the nucleus of many cancer cells by increasing its tran-
scriptionally activity, the use of ﬂavaglines could enhance the
exposure of p53 to PHB, attenuating the cell cycle and inducing apop-
tosis [3]. Moreover, ﬂavaglines such as rocaglamide, increases
phosphorylation of p53 and increases levels of the p53 regulated
pro-apoptotic protein Bax [57].
Moreover, as previously mentioned PHB has been identiﬁed to
improve the eﬃcacy of well-known licensed drugs such as Tamoxifen
by working in synergy with the drug. This could potentially become
another avenue for treatment, especially in terms of minimising che-
motherapy resistance.
Concluding remarks
The ability of PHB to interact with such an array of receptors,
proteins andmiRNAs in amultitude of disease states, as well as being
involved in oxidative stress and mitochondrial dysfunction makes
it a very unique protein. Potentially, PHB could have high clinical
relevance in the development of therapeutic agents. In particular
PHB could hold huge importance in unveiling themechanism to how
androgen stimulation down-regulates PHB expression in PC, which
is immensely signiﬁcant in deciphering how prostate tumours tran-
sition from androgen dependence to an apparent ‘androgen
independent’ state. This could also link to hormonally driven breast
cancer, whereby PHB can repress SRC-3 activation of ERα, inhibit-
ing both genomic and non-genomic ERα activation.
As cancers become increasingly aggressive and are rapidly pro-
liferating, the levels of mitochondria are also increased. Yet analysis
of cancers for PHB may have been misinterpreted as only protein
levels of PHB in the mitochondria have been examined. However
as demonstrated by this review nuclei andmembranous PHB as well
as its interactions with regulators of the cell cycle might also have
a major inﬂuence.
Furthermore, the research revealing how the cell cycle is inﬂu-
enced by PHB and its interaction with E2Fs, P53 and Rb can be
considered to have high relevance. These genes are frequently
mutated in almost all human cancers thus PHB may be key in regu-
lating their functions, especially in PC and breast cancer.
In summary, a growing body of evidence indicates that the sub-
cellular localisation of PHB is altered between tumour and normal
cells and that this alters PHB’s function. These various functions that
PHB carries out still requires further research, however it is clear
that its role is heavily implicated across an array of cancers. In par-
ticular, better understanding of its function within PC is potentially
making us one step closer to discovering therapies for androgen in-
dependent PC.
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